Epithelial Tumor clinical trials at UCLA

3 research studies open to eligible people

Showing trials for

  • First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

    open to eligible people ages 18 years and up

    To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.

    Los Angeles, California and other locations

  • NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

    open to eligible people ages 18 years and up

    This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.

    Santa Monica, California and other locations

  • NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

    open to eligible people ages 18 years and up

    This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours

    Santa Monica, California and other locations

Our lead scientists for Epithelial Tumor research studies include .

Last updated: